Preclinical Prediction of Resistance Mutations and Proposal of Sequential Treatment Strategies for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors

Yuki Takei(Pioneer (United States)), Kentaro Semba(Fukushima Medical University)
Pharmaceutical Research
September 1, 2025
Cited by 0


Related Papers